RATIONALE: Reports of cognitive decline, particularly in the domains of executive functions (EFs), are common among menopausal women. OBJECTIVE: This study aims to determine the impact of the psychostimulant lisdexamfetamine (LDX) on subjective and objective cognitive function among menopausal women who report new-onset EF complaints. METHODS:Thirty-two healthy perimenopausal and early postmenopausal women experiencing mid-life-onset executive function difficulties as measured using the Brown Attention Deficit Disorder Scale (BADDS) were administered LDX 40-60 mg/day for 4 weeks in this double-blind, placebo-controlled, cross-over study. Diagnosis of lifetime ADHD was exclusionary. BADDS total and subscale scores and performance on verbal memory and working memory tasks were outcomes of interest. RESULTS: Analyses revealed a significant effect of LDX treatment over placebo for total BADDS scores (p = 0.0001) and for four out of the five BADDS subscales (all p < 0.004). LDX treatment also resulted in significant improvement in delayed paragraph recall (p = 0.018), but there was no significant effect of treatment on other cognitive measures. Systolic blood pressure (p = 0.017) and heart rate increased significantly (p = 0.006) when women were on LDX but remained, on average, within the normal range. CONCLUSIONS:LDX 40-60 mg/day was well tolerated and improved the subjective measures of executive function as well as objective measures of delayed verbal recall in this sample of healthy menopausal women.
RCT Entities:
RATIONALE: Reports of cognitive decline, particularly in the domains of executive functions (EFs), are common among menopausal women. OBJECTIVE: This study aims to determine the impact of the psychostimulant lisdexamfetamine (LDX) on subjective and objective cognitive function among menopausal women who report new-onset EF complaints. METHODS: Thirty-two healthy perimenopausal and early postmenopausal women experiencing mid-life-onset executive function difficulties as measured using the Brown Attention Deficit Disorder Scale (BADDS) were administered LDX 40-60 mg/day for 4 weeks in this double-blind, placebo-controlled, cross-over study. Diagnosis of lifetime ADHD was exclusionary. BADDS total and subscale scores and performance on verbal memory and working memory tasks were outcomes of interest. RESULTS: Analyses revealed a significant effect of LDX treatment over placebo for total BADDS scores (p = 0.0001) and for four out of the five BADDS subscales (all p < 0.004). LDX treatment also resulted in significant improvement in delayed paragraph recall (p = 0.018), but there was no significant effect of treatment on other cognitive measures. Systolic blood pressure (p = 0.017) and heart rate increased significantly (p = 0.006) when women were on LDX but remained, on average, within the normal range. CONCLUSIONS:LDX 40-60 mg/day was well tolerated and improved the subjective measures of executive function as well as objective measures of delayed verbal recall in this sample of healthy menopausal women.
Authors: Pauline M Maki; Ellen W Freeman; Gail A Greendale; Victor W Henderson; Paul A Newhouse; Peter J Schmidt; Nelda F Scott; Carol A Shively; Claudio N Soares Journal: Menopause Date: 2010-07 Impact factor: 2.953
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: C Neill Epperson; Brian Pittman; Kathryn A Czarkowski; Jeanette Bradley; Donald M Quinlan; Thomas E Brown Journal: Menopause Date: 2011-05 Impact factor: 2.953
Authors: Thomas E Brown; Matthew Brams; Maria Gasior; Ben Adeyi; Thomas Babcock; Bryan Dirks; Brian Scheckner; Timothy Wigal Journal: Curr Med Res Opin Date: 2011 Impact factor: 2.580
Authors: Stephen R Rapp; Mark A Espeland; Joann E Manson; Susan M Resnick; Nick R Bryan; Sylvia Smoller; Laura H Coker; Lawrence S Phillips; Marcia L Stefanick; Gloria E Sarto Journal: Int J Psychiatry Med Date: 2013 Impact factor: 1.210
Authors: Sheila Shanmugan; Theodore D Satterthwaite; Mary D Sammel; Wen Cao; Kosha Ruparel; Ruben C Gur; C Neill Epperson; James Loughead Journal: Psychoneuroendocrinology Date: 2017-07-14 Impact factor: 4.905
Authors: Andrew M Novick; Anthony T Scott; C Neill Epperson; Christopher D Schneck Journal: Front Neuroendocrinol Date: 2020-08-18 Impact factor: 8.606
Authors: Sheila Shanmugan; James Loughead; Ravi Prakash Reddy Nanga; Mark Elliott; Hari Hariharan; Dina Appleby; Deborah Kim; Kosha Ruparel; Ravinder Reddy; Thomas E Brown; C Neill Epperson Journal: Neuropsychopharmacology Date: 2016-08-23 Impact factor: 7.853
Authors: Sheila Shanmugan; James Loughead; Wen Cao; Mary D Sammel; Theodore D Satterthwaite; Kosha Ruparel; Ruben C Gur; C Neill Epperson Journal: Neuropsychopharmacology Date: 2017-03-21 Impact factor: 7.853
Authors: Hillary B Nguyen; Alexis M Chavez; Emily Lipner; Liisa Hantsoo; Sara L Kornfield; Robert D Davies; C Neill Epperson Journal: Curr Psychiatry Rep Date: 2018-10-11 Impact factor: 5.285